Related Experiment Videos
Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features
M R Brunetto1, P L Calvo, F Oliveri
1Department of Gastroenterology, Molinette Hospital, Torino, Italy.
Insights
Hepatitis C virus (HCV) infection variability is linked to viral genetics. Detecting HCV RNA is crucial for diagnosing infections and monitoring treatment response, especially when antibodies are unreliable.
Area of Science:
- Hepatology and Virology
- Immunology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) infection presents a wide spectrum of liver disease, from asymptomatic carriage to severe chronic hepatitis.
- HCV's genetic heterogeneity contributes to variable pathogenicity, meaning virus presence doesn't always equate to liver damage.
- Standard IgM antibody tests for other viral hepatitis are insufficiently sensitive and specific for HCV diagnosis.
Purpose of the Study:
- To explore diagnostic and monitoring alternatives for Hepatitis C virus (HCV) infection.
- To evaluate the utility of anti-HCV antibodies and HCV RNA detection in different clinical scenarios.
- To assess the effectiveness of various antibody assays in predicting treatment response.
Main Methods:
- Review of diagnostic approaches for HCV infection, including antibody detection (anti-HCV) and HCV RNA quantification.
- Analysis of the correlation between serum anti-C100-3 and HCV RNA levels.
- Evaluation of immunoblotting assays for anti-HCV and quantitative assays for HCV RNA in monitoring antiviral therapy.
- Comparison of different anti-HCV antibody detection assays for their suitability in monitoring treatment response.
Main Results:
- Anti-HCV detection alone cannot distinguish past from present infections; seroconversion indicates recent infection.
- Serum anti-C100-3 is significantly associated with HCV RNA, suggesting anti-HCV as an indirect marker of infectivity.
- HCV RNA detection is a valid alternative for anti-HCV-negative infections and early acute hepatitis.
- Undetectable serum HCV RNA and/or decreasing anti-HCV titres predict successful antiviral therapy response.
- Anti-C22 is frequently detected early and often has the highest titre, while anti-C100 titres decrease sooner in responders.
Conclusions:
- HCV RNA detection offers a reliable diagnostic alternative, particularly in early or antibody-negative cases.
- Monitoring both anti-HCV by immunoblotting and HCV RNA by quantitative assays is valuable for predicting antiviral therapy outcomes.
- Broad antibody assays are unsuitable for monitoring due to their inability to track individual antibody disappearance.
- The natural course of HCV infection involves disease, carrier, and recovery phases, with prolonged disease potentially leading to severe liver issues.
Abstract:
Hepatitis C virus (HCV) infection is associated with a wide spectrum of liver disease ranging from asymptomatic carriage to severe forms of chronic hepatitis. HCV is not invariably pathogenic and genetic heterogeneity of HCV could be a major cause of such a variability. In clinical practice this means that presence and replication of the virus do not invariably imply a virus-induced liver damage. IgM antibodies that are the best diagnostic tools for the other forms of viral hepatitis are not sensitive and specific enough for hepatitis C, therefore we have to look for alternatives. Detection of anti-HCV does not help to distinguish past from present infections and only anti-HCV seroconversion in previously negative patients can indicate a recent HCV infection. However, the significant association between serum anti-C100-3 and HCV-RNA suggests that anti-HCV can be considered an indirect marker of HCV infectivity. In anti-HCV-negative infections and early acute hepatitis cases HCV-RNA detection will represent a valid diagnostic alternative. In patients undergoing antiviral therapy monitoring anti-HCV by immunoblotting assays and HCV-RNA by quantitative assays represent a valid tool to predict response that invariably has occurred in patients who had undetectable serum HCV-RNA and/or decreasing anti-HCV titres. Assays that detect multiple anti-HCV antibodies all together appear unsuitable for monitoring because they miss the disappearance of single antibodies. Anti-C22 appears the most frequent and earliest to be detected and usually it has the highest titre. Anti-C100 titres decrease earlier than anti-C33 and anti-C22 in patients with chronic HCV hepatitis who respond to antiviral therapy. The natural course of HCV infection appears to be characterized by three consecutive phases: disease, asymptomatic carrier and recovery. If transition from the first to the last occurs very slowly or the disease phase persists for years it may warrant in susceptible hosts severe forms of liver disease.